Share: Facebook Twitter LinkedIn
Activity Provided By:

University of Cincinnati and RedMedEd

Scale, Bail, or Fail – The CDK4/6 Inhibition Edition

Access Activity

Overview / Abstract:

Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way.

In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and discusses the latest updates on CDK4/6 inhibition research and its clinical implications. This activity also features downloadable resources (including supplemental figures and tables).

Expiration

Sep 06, 2018

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME

Format

Online

Credits / Hours

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation

ACCME

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Richard S. Finn, MD—Program Chair
Associate Professor of Medicine
University of California, Los Angeles
Los Angeles, California

Gary K. Schwartz, MD
Professor of Medicine
Chief, Division of Hematology and Oncology
Deputy Chief, Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

Geoffrey I. Shapiro, MD, PhD
Director, Early Drug Development
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Other

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through an educational grant from Pfizer.

Keywords / Search Terms

RedMedEd CDK4/6 inhibition, CDK4/6, oncology, oncologists, laboratory science, clinical investigators, mechanism of action, safety and efficacy data, solid tumors, clinical practice, University of Cincinnati, RedMedEd, RME, Free CME, CME, Free CE, interactive, game Free CE CME Live CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map